We serve Chemical Name:6,8-dibromo-2-phenylchromen-4-one CAS:42079-81-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6,8-dibromo-2-phenylchromen-4-one
CAS.NO:42079-81-2
Synonyms:6,8-Dibrom-2-phenyl-chromen-4-on;6,8-dibromo-2-phenyl-4H-chromen-4-one;6,8-dibromo-2-phenyl-chromen-4-one;6,8-dibromoflavone
Molecular Formula:C15H8Br2O2
Molecular Weight:380.03100
HS Code:2914700090
Physical and Chemical Properties:
Melting point:169-175ºC
Boiling point:470.3ºC at 760 mmHg
Density:1.795g/cm3
Index of Refraction:1.675
PSA:30.21000
Exact Mass:377.88900
LogP:4.98500
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6,8-Dibrom-2-phenyl-chromen-4-on chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6,8-dibromoflavone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6,8-dibromoflavone Use and application,6,8-dibromo-2-phenyl-chromen-4-one technical grade,usp/ep/jp grade.
Related News: Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 6,8-dibromo-2-phenylchromen-4-one manufacturer Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 6,8-dibromo-2-phenylchromen-4-one supplier In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances. 6,8-dibromo-2-phenylchromen-4-one vendor Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 6,8-dibromo-2-phenylchromen-4-one factory Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.
